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Abstract
Background. Diagnostic delays impact the quality of life and survival of patients with brain tumors. Earlier and
expeditious diagnoses in these patients are crucial to reduce the morbidities and mortalities associated with brain
tumors. A simple, rapid blood test that can be administered easily in a primary care setting to efficiently identify
symptomatic patients who are most likely to have a brain tumor would enable quicker referral to brain imaging for
those who need it most.
Methods. Blood serum samples from 603 patients were prospectively collected and analyzed. Patients either had
non-specific symptoms that could be indicative of a brain tumor on presentation to the Emergency Department,
or a new brain tumor diagnosis and referral to the neurosurgical unit, NHS Lothian, Scotland. Patient blood serum
samples were analyzed using the Dxcover® Brain Cancer liquid biopsy. This technology utilizes infrared spectroscopy combined with a diagnostic algorithm to predict the presence of intracranial disease.
Results. Our liquid biopsy approach reported an area under the receiver operating characteristic curve of 0.8. The
sensitivity-tuned model achieves a 96% sensitivity with 45% specificity (NPV 99.3%) and identified 100% of glioblastoma multiforme patients. When tuned for a higher specificity, the model yields a sensitivity of 47% with 90%
specificity (PPV 28.4%).
Conclusions. This simple, non-invasive blood test facilitates the triage and radiographic diagnosis of brain tumor
patients while providing reassurance to healthy patients. Minimizing time to diagnosis would facilitate the identification of brain tumor patients at an earlier stage, enabling more effective, less morbid surgical and adjuvant care.

Key Points
• This prospective, analyst-blinded clinical study demonstrates the clinical utility of a
spectroscopic brain cancer liquid biopsy which can effectively triage symptomatic
patients for investigative medical imaging for suspected brain tumors.
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Importance of the Study

This year in the United States, it is estimated that over 80
000 people will likely be diagnosed with a brain or central nervous system tumor.1 Although progress has been
made in the classification of these tumors, which comprise
over a hundred distinct types based on histopathologic criteria and immunohistochemical data set forth by the World
Health Organization, there is a very high fatality rate with
only one-third of patients surviving five years or more
after a diagnosis.2 This is likely due to diagnostic delays as
early symptoms of brain cancer are often nonspecific; for
example, headache is the most common symptom, hence
there is an excessive number of brain scans undertaken to
identify a tumor. Early detection is therefore challenging because of the range of disorders that these indicators can be
linked to.3,4 Delayed detection leads to 62% of brain tumor
patients receiving a diagnosis when they present to the
emergency department (ED) with advanced symptoms like
seizures and neurological deficits.5 Many of these patients
will have previously visited their primary care doctor on
several occasions with non-specific symptoms, and since
brain tumors are rare, a non-tumor diagnosis is much more
likely. Consequently, brain tumor patients see their primary
care physician on average three times before a final diagnosis.6 Early referral for brain imaging is crucial, but existing
symptom-based referral guidelines inadequately stratify patients for brain imaging based on suspicion of cancer which
may only be made after a lengthy process of eliminating
other conditions that are a part of differential diagnosis. The
National Institute for Health and Care Excellence (NICE) provides referral guidance in the UK, while the not-for-profit
organization National Comprehensive Cancer Network
(NCCN) provides this guidance in the USA. The maximum
positive predictive value (PPV) of NICE symptom-based referral guidelines for suspected brain cancer, for the presence of “symptoms related to the central nervous system,”
is only 2.9%.7 New rapid and affordable tests are required to
support clinical decision-making, with improved diagnostic
sensitivity and specificity so that at-risk patients do not fall
through the cracks of the healthcare system.
Liquid biopsy technologies, primarily based on blood
testing, have the potential to transform cancer diagnostics.8,9 Most liquid biopsies focus on a genomic approach
where genetic material, such as circulating tumor DNA
(ctDNA), is measured and quantified.10 This method relies upon the target ctDNA being released by the tumor
and navigating its way into the bloodstream, followed by

brain tumor. Here we present our results from
machine learning models that have been tuned
for greater sensitivity or specificity, since the
precise trade-off between these statistics is
likely to vary across international healthcare
systems. Our findings indicate the Dxcover®
Brain Cancer liquid biopsy has comparable
performance to commercially available tests
for other cancers.
amplification for detection. The amount of cancerous genetic material available for analysis is minute, and since
mutations in ctDNA can also be found in healthy individuals, it is very difficult to diagnose cancer with this strategy.
In fact, when the fraction of DNA is below only 1 cancer
genome to 10 000 normal genomes, even with 10 mL of
patient blood it is possible that there would be no single
genome available for sequencing.11 Additionally, ctDNA
is only found in 75% of patients with metastatic cancer.12
Importantly, not all tumors or tumor sub-types appear to
release ctDNA into the bloodstream, and some cancers are
known for their low ctDNA concentration (such as brain or
prostate cancer) adding to the poor reliability of genetic
markers, particularly for early-stage cancers which shed
such a low amount of ctDNA that current techniques are
incapable of detecting them.13–15
In brain cancer, a liquid biopsy could rapidly triage the
symptomatic population in a primary care setting with
a possible brain tumor diagnosis. The most at-risk patients could then be fast-tracked for urgent brain imaging.
A spectroscopic liquid biopsy is unique in that it produces
a biological signature, representing the whole biochemical profile of the serum sample and containing molecular
information from the host response as well as the tumor
(Supplementary Figure S1.).16 In a spectroscopic approach
the full range of biomarkers within blood serum is interrogated, rather than being limited to the analysis of individual molecular classes, such as ctDNA. We have recently
demonstrated that, unlike other liquid biopsies, the test
performance is insensitive to tumor size—down to as small
as 0.2 cm3—illustrating great promise for the deployment
of the technique for early detection and diagnosis.17
There are currently no available tests tailored for the early
detection and triage of brain cancer, yet there are several
that target other types of cancer. These tests focus on the
analysis of a symptomatic patient population and the results of the test are used to triage the patient towards medical imaging or back to the primary care clinician (Figure 1).
The SelectMDx test for prostate cancer, for example, is a
urine-based test that has been successfully launched in
the USA and Europe by MDxHealth.18 Likewise, the ExoDx
test is an exosome-based urine test that provides an individual risk score for clinically significant prostate cancer.19
Further examples include the Progensa PCA3 prostate
cancer test from HOLOGIC,20 Cologuard (Exact Sciences),
and Colox (Novigenix) tests for colorectal cancers,21,22 and
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This prospective, analyst-blinded clinical study
demonstrates the clinical utility of a spectroscopic brain cancer liquid biopsy which can
effectively triage symptomatic patients for investigative medical imaging for suspected
brain tumors. A simple, rapid blood test that
can be administered easily in a primary care
setting would enable quicker referral to imaging for those who are most likely to have a
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the EarlyCDT test (Oncimmune) for lung cancer.23 The use
of these tests supports the clinical utility of triage strategies within healthcare systems. A simple, rapid blood test
to support clinical decision-making in ruling out a possible
brain tumor in symptomatic patients would facilitate faster
diagnosis. Earlier diagnosis, when tumors are smaller, can
expedite access to life-saving treatments, increase the success of these interventions, and reduce harm from more
invasive surgeries and aggressive therapies. The novel
Dxcover® Brain Cancer liquid biopsy uses infrared (IR)
light to interrogate patient blood sera. Indicators of disease
are present within the generated spectroscopic signature
and are accentuated and classified by a diagnostic machine learning algorithm. The results of the liquid biopsy
will facilitate clinical decision-making to determine the appropriate referral path for at-risk patients. A positive result
would indicate an increased risk for brain cancer and the
patient would be expedited to imaging to receive a diagnosis much earlier than if they had not received the liquid
biopsy test. A negative result would inform the patient
and provider that there is not an increased risk of brain
cancer and the patient would receive care in accordance
with routine follow-up protocols and procedures based on
clinical judgment. Patients, for whom the predicted risk of
cancer is low, could avoid the potential harm from brain
imaging in terms of radiation and the identification of incidental abnormalities prompting further investigations or
treatments. Furthermore, the potential for cost savings has
also been demonstrated when considering the reduction
in unnecessary brain scans, as well as reducing the burden
on hospitals and clinicians, and other preventable tests or
procedures.24,25
Over the past decade, the differentiation between brain
cancer and non-cancer has been investigated using this
approach, first utilizing retrospectively collected serum
samples from biobank facilities.26–31 Moreover, we recently
illustrated the potential to distinguish between various
brain tumor subtypes.32 To explore the true clinical utility,
the first prospective study in a targeted medical environment was conducted using the spectroscopic liquid biopsy from patients referred by their primary care doctor
for urgent brain imaging.33,34 This landmark study achieved
92% sensitivity for the most common brain tumor—glioblastoma multiforme (GBM)—and 81% sensitivity for all
brain tumors, with 80% specificity. We now present data on
samples collected from 603 patients in a more challenging

cohort of symptomatic patients, which includes the presence of other serious medical conditions presenting in the
emergency department, such as stroke. This accurately
represents the target population and consideration of
these other pathologies is key for patient triage, as these
pathologies will statistically be the more likely ailment
when patients present with non-specific symptoms. We report the clinical utility of the brain cancer blood test within
this cohort and assess how the diagnostic models can be
tailored towards higher sensitivity or specificity depending
on clinical priorities.

Materials and Methods
Patient Sample Selection
Ethical approval for this study was granted by Lothian
REC (15/ES/0094). Blood samples were gathered at three
different collection sites, from patients representing a diverse, urban patient population and aged 16 years or older
were eligible for inclusion, encompassing different points
on the cancer referral and diagnosis pathway.
1. Patients referred by their primary care doctors in
Lothian (UK) who have direct access CT (DACT) brain
imaging for exclusion of significant intracranial pathology, where urgent (same day) brain imaging is
not required. All DACT brain imaging is performed in a
single neuroradiological department at the Department
of Clinical Neurosciences, Western General Hospital,
Edinburgh, Scotland. Patients referred for DACT or
within the brain cancer population, who were able to
provide informed consent, were invited to participate.
2. Patients presenting to the Emergency Department of the
Royal Infirmary of Edinburgh with a new severe onset
neurological symptom—eg, seizures, fainting, memory
loss, vision change etc.—with no history of trauma, where
the assessing clinician judged brain imaging was necessary and that the differential diagnosis included a brain
tumor. Patients aged 16 years or older, who were able to
provide informed consent were invited to participate.
3. Patients with a new brain tumor diagnosis, scheduled
for surgery at the Western General Hospital, Edinburgh,
NHS Lothian, were also invited to participate prior to
surgery.
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Figure 1. Patient pathway with the addition of a brain cancer liquid biopsy for triage.
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Patient Sample Analysis
Patient serum samples were analyzed using the Dxcover®
Brain Cancer liquid biopsy. For further details, we direct the
reader to the following articles.33,34 In this study, patient
whole blood samples were collected and processed on-site
via standard clinical sample preparation procedures prior
to brain imaging or brain tumor surgery at the Western
General Hospital, Edinburgh, NHS Lothian. The resultant
serum samples were stored at –80°C until the date of analysis. The serum samples were allowed to thaw for up to
30 minutes at room temperature (18–25°C) and inverted
three times to ensure sufficient mixture and thawing. Each
patient sample was prepared by pipetting 3 μL of serum
onto three sample wells of the Dxcover® Sample Slides
(Dxcover®, Glasgow, UK). Prepared slides were placed in
a drying unit incubator (Thermo Fisher™ Heratherm™, GE)
at 35°C for 1 hour, to control the dehydration process of
the serum droplets.35 The dried sample slides were loaded
on to the Dxcover® Autosampler (Dxcover®, Glasgow, UK)
and prepared for spectral collection. In this study, a Perkin
Elmer Spectrum 2 FTIR spectrometer (Perkin Elmer, USA)
was used to generate spectral data (16 co-added scans at
4 cm–1 resolution, with 1 cm–1 data spacing). A total of three
spectra were collected for each sample well, resulting in
nine replicates per patient. The 9 patient spectra were fed
into the diagnostic algorithm which generates the disease
prediction. Anonymized samples were reported as brain
cancer positive or negative according to spectroscopy test
results.

Algorithm Training
Following spectral acquisition, the nine spectra obtained
from each patient sample were analyzed using the
Dxcover® Brain Cancer Algorithm—a machine learning
model trained and tuned to accurately detect the signal
of brain cancer. This algorithm was trained on 385 prospectively recruited patients,34 which were distinct from
the 603-patient blind test set (Supplementary Table S1).
This model was chosen through a nested cross-validation

approach, in which 5-fold cross-validation was used to
optimize model hyperparameters and the probability
threshold. This was repeated for 51 separate train-test
splits to obtain a robust measure of the performance of the
model. The model was then retrained on the full 385-patient dataset using the optimal hyperparameters and
probability threshold and predictions were made on the
analyst-blinded 603-patient cohort, the results of which are
presented in this paper.

Disease Prediction
A consensus prediction was determined from the 9 spectra
acquired from each patient. In cases where 5 or more
spectra were predicted as positive then a positive result
was reported for the patient. Receiver operating characteristic (ROC) curves were generated by altering the
probability threshold of the algorithm between cancer
and non-cancer and noting the corresponding sensitivity
and specificity. In this study, disease predictions were
generated for the anonymized cohort of patients and
were submitted for review as part of the interim analysis.
Throughout this process, analysts and operators were
blinded to the true patient disease class and lead clinician Dr. Paul Brennan was responsible for unblinding
and reporting test performance against CT. The reference
standard in this study was CT imaging, to confirm or refute
evidence of central nervous system tumors, followed by
diagnosis by biopsy if clinically indicated.

Results
Patient Cohort Data
A total of 1981 patients from a diverse, urban population
were screened for eligibility based on the primary care referral pathway for brain imaging. The flow of participants
is highlighted in Figure 2. The age and sex breakdown of
the 603 patients included in this study are presented in the
supplementary material (Supplementary Table S2). While
we did not stratify based on race/ethnicity, these patients
represented a diverse, urban patient population. In total,
47 patients had a confirmed brain tumor, resulting in a
prevalence of 7.8%. The most common and malignant brain
tumor in adults—glioblastoma (GBM)—was found to be
the most prevalent in this population (n = 20). There were
also 12 brain metastases observed: breast (n = 6), lung (n
= 4), and esophagus (n = 1), metastatic tumor of unknown
primary (n = 1). The remaining tumors were meningioma
(n = 10), low-grade glioma (n = 2), primary central nervous
system lymphoma (n = 2), and medulloblastoma (n = 1).
The final diagnosis for the non-cancer patients is also described in the supplementary information (Supplementary
Table S3).
Test performance was determined by comparison of the
test prediction against the reported diagnosis confirmed
via CT brain imaging. Predictions of the clinical data were
performed in an analyst-blind fashion before comparison
with the clinical data. To analyze this data, the area under the
curve (AUC) of the ROC curve is a useful metric to assess
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Investigators obtained written informed consent from all
study participants. In DACT patients a blood sample was
collected via venepuncture during their attendance for
brain imaging appointments. In collection sites 2 and 3, a
blood sample was taken during a clinical assessment.
Blood samples were obtained during routine venepuncture using S-Monovette 7.5 ml Serum Gel Z collection tubes
(Sarstedt, Germany) and anonymized for processing and
analysis. Each sample was gently inverted 8 times and allowed to clot. Centrifugation was performed for 15 minutes
at 2200 g (or equivalent) and stored in a –80°C freezer. Data
interpretation was blinded to brain imaging and histological diagnosis; imaging outcomes were recorded from the
formal radiological report and histological tumor diagnosis
was available for patients that underwent surgery. Clinical
data were entered into an online database designed and
supported by Edinburgh Clinical Trials Unit, which meets
standards on data security and participant privacy and
confidentiality.
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Total number of
participants screened
(n = 1981)

Excluded due to:
• Did not attend (n = 1)
• Incapacity to consent (n = 385)
• Traumatic cause (n = 52)
• Underage (n = 23)
• Left department (n = 43)
• Already recruited (n = 5)
• Blood-borne virus (n = 4)
• No CT (n = 648)
• Language barrier (n = 25)
• Declined (n = 99)
• Inappropriate to approach (n = 75)
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Potentially eligible
participants (n = 621)

Excluded due to:
• Post-operative/duplicate
collection (n = 16)
• Consent withdrawn (n = 2)

Eligible participants
(n = 603)

Figure 2. Flow of participants through prospective recruitment for the clinical validation study.
  

  
1.0

0.8

Sensitivity

the inherent validity of the diagnostic test.36 The ROC curve
shown in Figure 3. reports an AUC value of 0.8, which indicates the test has an excellent discriminating ability.37
Sensitivity or specificity can be maximized depending
upon the requirements of the diagnostic pathway and
healthcare system. For example, sensitivity (or specificity)
can be augmented while ensuring the specificity (or sensitivity) is at an approximate value. If greater sensitivity
is required, we can achieve 96% sensitivity (green circle)
with a 45% specificity. If a higher specificity is desired (blue
circle), a 90% specificity results in a 47% sensitivity. The
full breakdown of diagnostic performances for both approaches (sensitivity- and specificity-tuned) in the 603 patient population is summarized in Table 1.
The predictions by brain tumor type, for the model tailored for greater sensitivity, are shown in Table 2. The detection rates for the specificity-tuned model can be found
in Supplementary Table S4. Significantly, the sensitivitytuned algorithm detected 100% (20/20) of GBM patients
correctly, the most common and aggressive adult brain
tumor. The Dxcover® Brain Cancer liquid biopsy also
predicted 100% of the metastatic (n = 12), lymphoma
(n = 2), and medulloblastoma (n = 1) tumors, and 90% of
meningiomas (n = 10) were detected successfully. Of the
two low-grade gliomas in this cohort, one was predicted
correctly.

0.6

0.4

AUC = 0.8

0.2

Sens = 0.96
Spec = 0.45
Sens = 0.47
Spec = 0.9

0.0
1.0

0.8

0.6

0.4

0.2

0.0

Specificity
Figure 3. Receiver operating characteristic (ROC) curve, showing
the trade-off between sensitivity (Sens) and specificity (Spec) at
varying probability thresholds. Blue circle, sensitivity-tuned; Green
circle, specificity-tuned. AUC; area under the curve.
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Table 1. Summary of Diagnostic Performance for Both the
Sensitivity-Tuned and Specificity-Tuned Algorithms
Sensitivity-tuned

Specificity-tuned

Sensitivity

96%

47%

Specificity

45%

90%

Prevalence

7.8%

7.8%

PPV

12.9%

28.4%

NPV

99.3%

95.3%

Discussion

PPV, positive predictive value; NPV, negative predictive value.

  
Table 2. Detection Rates by Brain Tumor Type for the SensitivityTuned Algorithm
Tumor Type

Actual

Identified

Detection
Rate (%)

GBM

20

20

100

Meningioma

10

9

90

Metastatic

12

12

100

Lymphoma

2

2

100

Low grade glioma

2

1

50

Medulloblastoma

1

1

100

47

45

96

  
The spectral regions, or specific wavenumbers, that contribute to a classification can be assessed by feature importance analysis. The wavenumber regions that were found
to be most discriminatory for the can be visualized in importance plots (Supplementary Figure S2). The top 5 regions of importance are described in Supplementary Table
S5, with tentative biological assignments and their corresponding vibrational modes.38

Patient Metadata
We explored patient metadata was explored to assess any
impact on the diagnostic predictions of the brain cancer
liquid biopsy test. Supplementary Table S2. outlines the patient metadata breakdown of the 603 patients involved in
this study. Upon analysis of demographic and clinical characteristics, no distinct patterns were observed. In particular,
patient age did not significantly affect either the sensitivitytuned or specificity-tuned models (Supplementary Figure
S2). The detection rates for both models when split by
sex, head pain, and personality change are described in
Supplementary Table S6, neither of which indicate any concerns about these potential confounding factors. Since
many non-cancer patients in the cohort had a stroke diagnosis, we further assessed whether this would have an
effect on the diagnostic predictions. The detection rates
for the patients with and without stroke were examined
(Supplementary Table S6), and it can be deduced that stroke
does not appear to have an influence on the test performance. This shows great promise as it indicates that the

We examined the clinical utility of a spectroscopic-based
liquid biopsy on prospectively collected samples from patients with proven or suspected brain cancer. The study
was designed to provide a cohort of patients that are as
close as possible to the target population of those with
non-specific symptoms of head pain and/or neurological
deficits, which may be indicative of a brain tumor. Our
findings demonstrate the significant impact this rapid,
cost-effective test can have in supporting earlier diagnosis of brain tumors.
There were 47 brain tumors diagnosed in this 603-patient
cohort. The test performance was effective in predicting
GBM, glioma, lymphoma, and metastatic cancers. These
are the most common and aggressive types of brain tumors which require rapid instigation of therapy and will
benefit most from earlier diagnosis. There is a reduction
in the morbidity of brain tumor surgery and radiotherapy
when clinicians can diagnose brain tumors at an earlier
stage when these tumors may have a significantly smaller
volume/mass. When tuned for a greater sensitivity the brain
cancer liquid biopsy also identified 9/10 meningiomas.
Although meningiomas may not require urgent surgical
intervention, detecting these more indolent tumors would
give patients and their clinicians invaluable information directly influencing the monitoring, management, and treatment of their condition.
The symptoms most common in brain tumor patients
are non-specific and the prevailing diagnostic paradigm,
dependent on the clinical history and examination to
guide brain imaging referral patterns, is largely ineffective. This is evidenced by the 62% of patients who remain
undiagnosed until symptoms force them to appear in the
ED,5 the excessive number of primary care consultations
for each patient before diagnosis, and the very low diagnostic rate from imaging referrals—a recent study showed
that for every 60 brain scans only 1 will result in a brain
tumor.39 Crucially, the Dxcover® Brain Cancer liquid biopsy can significantly enhance this existing cancer referral
pathway, supporting expert clinical decision-making.
Since this liquid biopsy involves a simple, non-invasive
blood test, with a fast turnaround time (24–48 hours or
earlier) it can be used in any clinical setting. Incorporating
this technology into the primary care setting, particularly
in areas where access to specialists and more advanced
medical equipment may be limited, could help to reduce
health care disparities for vulnerable populations. In addition, incorporating this tool into existing referral protocols
could save time, money, and assets by avoiding unnecessary imaging, additional tests/follow-up procedures, and
reducing the burden on limited resources and staff. The
impact of an early and efficient diagnosis can be the determining factor in these patients’ prognosis and outcome
while contributing to considerable savings in costs for patients and healthcare systems.
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brain cancer liquid biopsy is accurate, robust, and dependable in clinical applications where patients may have confounding characteristics and co-morbidities that may result
in the presentation of similar non-specific symptoms.
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In a population of symptomatic patients with suspicion of brain cancer who are referred for brain imaging,
the actual proportion of brain tumor diagnoses is approximately 1%.39 To estimate the impact of the liquid biopsy
(Supplementary Table S7), if we assume a 1% prevalence
amongst 10 000 symptomatic patients being tested, then
100 would likely have brain tumors.39 A recent case-control
study reported a sensitivity of 14.2% for headache alone,
meaning based on the current pathway only 14 of the 100
brain tumor patients would receive a timely diagnosis.42
However, with our sensitivity-tuned algorithm 96 of these
patients would receive a positive result and receive an urgent referral to imaging for confirmation of the diagnosis.
These patients will obtain a much more timely a diagnosis
than current standard care. The other 4 would be referred
for imaging only when they present with persistent, additional, or worsening symptoms. Such “safety netting” for
symptom progression is a standard part of clinical care.
If a physician remains concerned about a possible cancer
diagnosis despite a negative liquid biopsy test, brain imaging could still be arranged. In addition, 38% of brain
tumor patients visit their doctor more than five times prior
to diagnosis. Even if the liquid biopsy test did not identify
a patient’s tumor initially, a repeated blood test at a subsequent visit could still enable quicker referral saving precious diagnostic and therapeutic time and resources. For
the sensitivity-tuned model, 4455 of the 9900 patients
without a brain tumor would receive a negative result and
have a routine follow-up. The 5445 patients who received
false positives would be fast-tracked for imaging. It is likely
these patients would have been offered a brain scan eventually based on the current pathway, yet a quicker referral
would allow clinicians to rule out a brain tumor earlier. In
particular, this technology would be useful to patients with
an inherited predisposition or those requiring surveillance.
A simple blood test that can detect tumors early and easily
could be a beneficial and cost-effective part of the standard
screening protocols for these patients.
With our specificity-tuned model, 47 out of the 100 brain
tumor patients will receive a positive result and get an urgent referral for imaging. Among the 9900 patients without
a brain tumor, 8910 would receive a negative result with
our specificity-tuned algorithm. Thus, with fewer falsepositive tests than the sensitivity tuned model the cost of
imaging would be markedly lower, with fewer incidental
findings anticipated. The 53 brain tumor patients who received a false negative result but have clinical symptoms
that fall within standard risk guidelines, would still meet
eligibility requirements to obtain a diagnosis along the
standard diagnostic pathway, either because the physician
refers them directly for brain imaging as they remain concerned about the patient, or because the patient later presents with persistent or progressive symptoms. A repeated
blood test at a follow-up visit could still enable quicker referral. In either case, the time to diagnosis will have been
substantially decreased for 47% of patients, potentially unchanged for 53% of patients, and the overall referral for imaging markedly reduced.
In our 10 000 (1% prevalence) population, with a single
computed tomography (CT) brain scan costing approximately £90 in the UK, the savings for the NHS could be
substantial.24 With the specificity-tuned algorithm we

Neuro-Oncology
Advances

Current guidelines in the UK to support primary care
doctors in identifying patients most at-risk of having a
brain tumor include the Kernick referral criteria that utilize
a red/orange/yellow flagging system to reflect three levels
of risk for brain tumor.40 Similarly, the 2005 NICE referral
guidelines include details of symptoms that should prompt
urgent referral, consideration of urgent referral, or nonurgent referral.41 Despite having this guidance in place, it is
still extremely difficult for physicians to know whether their
patients should be expedited for a brain scan. Thus, the existing referral guidelines are still insufficient in stratifying
patients based on their symptoms.7 In both orange and
yellow flag groups many patients with brain cancer will not
be referred for imaging until prompted by costly symptom
progression.
A blood test for brain cancer would reduce the proportion of patients being diagnosed in ED as well as the
number of unnecessary medical imaging tests performed,
thus releasing pressure on the imaging system and saving
healthcare costs. Within our previously published health
economic studies, we assume half of the patients with a
negative result will still undergo imaging.24,25 With the
lower cost of the blood test compared to imaging, and with
up to 50% fewer brain scans, not only would a brain cancer
liquid biopsy be economically effective but all patients
waiting for imaging would be scanned quicker. In patients
presenting to their primary care doctor, where a brain
tumor is suspected, a positive blood test result will permit
the prioritization of that patient for brain imaging, reducing
the risk that they present to the ED with preventable clinical deterioration while awaiting delayed diagnostic brain
imaging. Furthermore, a positive result in our liquid biopsy
could potentially negate the need for a CT scan, with risk
of radiation and imperfect sensitivity for tumors, it may be
preferred to proceed directly for an MRI scan. A negative
blood test, if consistent with the physician’s clinical assessment of low likelihood of a brain tumor, would enable the
avoidance of brain scanning. If clinical suspicion persists
despite a negative blood test, further clinical assessment
or investigations can be arranged.
A recent study examining the NICE 2005 and Kernick referral guidelines for symptoms suggestive of brain tumor
reported a PPV of 2.9% and 2.8% for the ’symptoms related to CNS’ and “red flag symptoms” respectively, the
categories of highest perceived risk.7 On an equivalent
basis, our sensitivity-tuned model indicates a PPV of 12.9%,
thus providing more than a 100-fold improvement in detection when compared to headache alone, which has a 0.1%
PPV.42 This is also greater than the highest published PPV
(7.2%) which was associated with a combination of symptoms (headache, cognition, concentration, and confusion
symptoms) over a prolonged 6-month period where the
disease will be progressing.42 Furthermore, the PPV of the
Dxcover® Brain Cancer liquid biopsy increases when utilizing the specificity-tuned model, with a reported value of
28.4%. However, a high NPV is imperative for a triage test,
particularly for early detection of cancer as it defines the
probability that the patients with a negative test result truly
do not have the disease. In other words, it is vital to have a
low number of false negatives, meaning the negative predictions are indeed true negatives. Our results indicate this
would be achievable, with an extremely high NPV of 99.3%.
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Table 3. Comparison of the Diagnostic Performance of the Sensitivity-Tuned Model Against Commercially Available Liquid Biopsies for Cancer44,45
Liquid Biopsy

Targeted
Cancer

Patient
Cohort

Sensitivity (%)

Specificity (%)

Prevalence (%)

NPV (%)

AUC

Dxcover®
Brain Cancer (Dxcover Ltd.)

Brain

603

96

45

7.8

99.3

0.8

Select MDx
(MDx Health)

Prostate

916

93

47

26

95

0.85

ExoDx
(Exosome Dx)

Prostate

503

90

38.6

32

89.3

0.71

NPV, Negative predictive value; AUC, area under the curve.

would significantly reduce unnecessary medical imaging
on these patients. As well as CT, many patients in the diagnostic pathway will undergo magnetic resonance imaging
(MRI) in the UK, which is more expensive and costs around
~£165 per scan.25 In the US, these costs can be much
higher and can vary drastically depending on many factors
including whether or not the patient has health insurance,
the clinician or hospital is within the network, the particular
equipment available, the clinical setting where the procedure is performed, and the geographical location among
other factors. Costs for MRIs for example, can range from
$375 to $2850 with the US national average cost around
$1325, while costs for brain CT scans can range from
$825 to $4800 with the national average cost around
$1200.43,44 Supplementary Table S8 overviews the potential
cost savings with this scenario in the UK and US. For the
sensitivity-tuned model, it is estimated that the UK’s NHS
could save around £1 136 025 per 10 000 patients. Likewise,
with scans being more expensive in the US, approximately
$11 248 875 could be saved with the use of the sensitivitytuned model. Utilization of the specificity-tuned model
would enable even greater cost savings, with ~£2 272 050
in the UK and $22 497 750 in the US. It is worth noting that
the estimates presented here are solely based on the costs
of brain scans, and do not consider the additional expenditures for neuropathology outpatient appointments and
numerous primary care visits, which with the addition of
the liquid biopsy could be avoided for a substantial proportion of patients. The precise trade-off between sensitivity
and specificity may be specific to different regional and
national healthcare systems and clinician discretion. From
either perspective, a brain cancer liquid biopsy reduces
the total number of brain imaging investigations needed,
decreasing time to diagnosis for patients with a positive
blood test and an actual tumor, as well as significantly reducing overall healthcare costs and resources.24,25
There are no currently available triage tests for brain
cancer, but a commercial comparator for clinical benchmarking can be provided by the Select MDx test for prostate
cancer (MDx Health).18 In a similar fashion to the use of the
Dxcover® Brain Cancer liquid biopsy, this test is directed at
symptomatic patients who have an abnormal prostate-specific antigen (PSA) level or abnormal digital rectal exam
(DRE). The results from the Select MDx genomic urine liquid
biopsy are used to decide if the patient moves forward with
medical imaging followed by biopsy or just to routine PSA
follow-up.45 Another potential comparator is the ExoDx test,

commercialized by the company ExosomeDx.19 The ExoDx
test is a urine-based liquid biopsy that provides a risk score
to determine a patient’s risk of clinically significant prostate
cancer on a prostate biopsy.46 When comparing the diagnostic performance of these commercial tests against the
results from our 603-patient dataset, the Dxcover® Brain
Cancer liquid biopsy sensitivity-tuned model performs favorably (Table 3), highlighting that our simple blood test can be
as effective as commercially available tests for cancer.
The optimum balance of sensitivity and specificity will
be informed by the specific healthcare system in which
the test is being applied and the discretion of the physician using the test. A reduction in specificity increases
the false-positive results which will likely result in more
brain imaging, whilst a reduction in sensitivity will
increase the possibility that a patient with a tumor will
be initially missed. There is arguably the most value to be
gained in detecting some, but not all, brain tumors earlier.
Significantly more false-positive results would ultimately
lead to increased number of referrals for brain imaging,
which may be less welcome. Hence the optimum balance
may favor specificity more than sensitivity. In addition,
the barrier for access to a blood test may be substantially
lower than the barrier for access to more costly medical
imaging tests, meaning more blood tests can be easily
conducted. The integration of a brain cancer liquid biopsy into existing pathways would permit more effective
triage of patients, expediting assessment for those most
at-risk whilst excluding a brain tumor diagnosis in others.
By decreasing the time to diagnosis, the morbidity from
treatment can be reduced, which in turn would improve
the quality of life of brain cancer patients, resulting in a
greater prognosis.

Supplementary material
Supplemental material is available at Neuro-Oncology
Advances online.
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